AIC
PRQR icon

AWM Investment Company’s ProQR Therapeutics PRQR Stock Holding History

AWM Investment Company’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-166,667
Closed -$617K – 125
2022
Q4 		$617K Buy
+166,667
New +$218K 0.09% 97

Other funds holding PRQR

PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

AWM Investment Company's PRQR Position: Q1 2023 in Review

AWM Investment Company sold out of ProQR Therapeutics (PRQR) in Q1 2023, closing a stake of 166,667 shares — an estimated $617K sold.

AWM Investment Company first reported a position in PRQR in Q4 2022 and held it in 1 quarter. The position peaked at $617K in Q4 2022. 55 funds tracked by Wall St. Rank hold PRQR as of Q1 2023.

  • AWM Investment Company reported no remaining ProQR Therapeutics position as of Q1 2023 after selling out during the quarter.
  • AWM Investment Company sold 166,667 ProQR Therapeutics shares in Q1 2023, an estimated $617K.
  • AWM Investment Company first reported a position in ProQR Therapeutics in Q4 2022 and held it in 1 quarter.
  • AWM Investment Company's ProQR Therapeutics position peaked at $617K in Q4 2022.
  • 55 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2023.

Based on AWM Investment Company's 13F filing for Q1 2023, filed 12 May 2023.